We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Randomized Phase III Trial of Neoadjuvant Chemotherapy in Head and Neck Cancer: 10-Year Follow-Up.
- Authors
Zorat, Pier Luigi; Paccagnella, Adriano; Cavaniglia, Giancarlo; Loreggian, Lucio; Gava, Alessandro; Mione, Carlo Alberto; Boldrin, Fanny; Marchiori, Carlo; Lunghi, Francesco; Fede, Antonella; Bordin, Alessandro; Da Mosto, Maria Cristina; Sileni, Vanna Chiarion; Orlando, Antonio; Jirillo, Antonio; Tomio, Luigi; Pappagallo, Giovanni Luigi; Ghi, Maria Grazia
- Abstract
In 1986, we initiated a multicenter, randomized trial to compare induction chemotherapy with cisplatin and 5-fluorouracil followed by locoregional treatment (surgery and radiotherapy or radiotherapy alone) with loco-regional treatment alone in patients with head and neck squamous cell carcinoma. Here we report the long- term results of the trial. A total of 237 patients with nonmetastatic stage III or IV head and neck carcinoma were randomly assigned to receive four cycles of neoadjuvant chemotherapy followed by locoregional treatment (group A) or locoregional treatment alone (group B). Among all patients, overall survival at 5 and 10 years was 23% (95% confidence interval [CI] = 15.3% to 30.9%) and 19%(95% CI = 11.6% to 26.4%), respectively, for those in group A and 16% (95% CI = 9.6% to 23.4%) and 9% (95% CI = 3.5% to 14.7%), respectively, for those in group B (P = .13). Among operable patients, we observed no difference between group A and group B in overall survival at 5 and 10 years (group A, 31% [95% CI = 14.9% to 47.3%] and 22.7% [95% CI = 7.1% to 38.3%], respectively; group B, 43.3% [95% CI = 25.6% to 61.0%] and 14.2% [95% CI = 0.1% to 28.3%], respectively; P = .73). Among inoperable patients, overall survival at 5 and 10 years was 21 % (95% CI = 123% to 30.1%) and 16% (95% CI = 7.7% to 23.9%), respectively, for group A and 8% (95% CI = 1.5% to 12.3%) and 6% (95% CI = 0.1% to 9.1%), respectively, for group B (log-rank P = .04). Four cycles of neoadjuvant chemotherapy is a promising approach for treating patients with inoperable advanced head and neck cancer but not for treating patients with operable disease.
- Subjects
CANCER chemotherapy; ADJUVANT treatment of cancer; CANCER treatment; HEAD &; neck cancer treatment; THERAPEUTICS
- Publication
JNCI: Journal of the National Cancer Institute, 2004, Vol 96, Issue 22, p1714
- ISSN
0027-8874
- Publication type
Article
- DOI
10.1093/jnci/djh306